Compare ATON & PPCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | ATON | PPCB |
|---|---|---|
| Founded | 1973 | 2007 |
| Country | British Virgin Islands | Australia |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | |
| Sector | Energy | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.8M | 5.7M |
| IPO Year | N/A | N/A |
| Metric | ATON | PPCB |
|---|---|---|
| Price | $0.52 | $0.22 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 4.7M | 3.2M |
| Earning Date | 02-27-2026 | 02-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.46 | $0.16 |
| 52 Week High | $15.82 | $11.00 |
| Indicator | ATON | PPCB |
|---|---|---|
| Relative Strength Index (RSI) | 38.84 | 34.63 |
| Support Level | $0.46 | $0.16 |
| Resistance Level | $0.59 | $0.24 |
| Average True Range (ATR) | 0.06 | 0.04 |
| MACD | 0.02 | 0.02 |
| Stochastic Oscillator | 9.62 | 29.09 |
AlphaTON Capital Corp is a specialized digital asset treasury company focused on building and managing a strategic reserve of TON tokens and developing the Telegram ecosystem. The company implements a comprehensive treasury strategy that combines direct token acquisition, validator operations, and strategic ecosystem investments to generate sustainable returns for shareholders. Through its operations, it provides public market investors with institutional-grade exposure to the TON ecosystem and Telegram's billion user platform.
Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.